Transphorm price target lowered to $3.50 from $4.50 at B. Riley

B. Riley lowered the firm’s price target on Transphorm to $3.50 from $4.50 and keeps a Neutral rating on the shares post the fiscal Q1 report. The analyst seeks signs of a more material and durable sales and margin expansion and a clearer path to profitability to tilt more positive on the shares.